Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

NCT01131325 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

CML
Philadelphia Chromosome Positive (Ph+)
Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels

Interventions

DRUG: nilotinib

Sponsor

Novartis Pharmaceuticals